Showing 2511-2520 of 2839 results for "".
- RealSelf Adds One Million Arabic-speaking Monthly Users With Tajmeeli.com Acquisitionhttps://modernaesthetics.com/news/realself-adds-1-million-arabic-speaking-monthly-users-with-tajmeelicom-acquisition/2473043/RealSelf now owns Tajmeeli, the leading cosmetic procedure resource for Arabic speaking consumers. The acquisition adds one million Arabic-speaking monthly active users. "We're excited this acquisition will enable us to expand our reach and resources to over 100 countries
- Soliton Taps Sean J. Shapiro as Vice President of Saleshttps://modernaesthetics.com/news/soliton-taps-sean-j-shapiro-as-vice-president-of-sales/2473037/Sean J. Shapiro is Soliton, Inc’s New Vice President of Sales, effective January 1, 2021. "We are very excited to have Sean join our team during this pivotal time for the company as we anticipate clearance of our 510(k) application for cellulite reduction duri
- Revance Therapeutics and Ajinomoto Bio-Pharma Services Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://modernaesthetics.com/news/revance-therapeutics-and-ajinomoto-bio-pharma-services-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2473035/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.
- Done Deal: DermOQ Oxygen Lab Acquires ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://modernaesthetics.com/news/done-deal-dermoq-oxygen-lab-acquires-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2473034/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom
- Phase 2 DaxibotulinumtoxinA Data Highlight Efficacy for Upper Facial Lineshttps://modernaesthetics.com/news/phase-2-daxibotulinumtoxina-data-highlight-efficacy-for-upper-facial-lines/2473032/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- 2020 in Reviewhttps://modernaesthetics.com/news/2020-in-review-1/2473031/• The AmSpa Aesthetic Safety Council (AASC), designed to help the American Med Spa Association (AmSpa) further its goal of promoting compliance, safety, and profitability throughout the medical aesthetic industry, has launched. Even in the midst of the international COVI
- Revance Names Nashville Its New Homehttps://modernaesthetics.com/news/revance-names-nashville-its-new-home/2473029/Revance Therapeutics is relocating to Nashville. In conjunction with Tennessee Gov. Bill Lee and Tennessee Department of Economic and Community Development (TNECD) Commissioner Bob Rolfe, the company says it is leaving its current home in Silicon Valley’
- HydraFacial To Go Public After SPAC Dealhttps://modernaesthetics.com/news/hydrafacial-to-go-public-after-spac-deal/2473028/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- Demandforce Launches Online Booking Functionalityhttps://modernaesthetics.com/news/demandforce-launches-online-booking-functionality/2473020/Demandforce has launched Demandforce Online Booking, a new functionality that makes it easier for clients of Demandforce business users to schedule appointments online while enabling businesses to manage their appointment sche
- Promising Results from Dysport Dose Escalation Studyhttps://modernaesthetics.com/news/promising-results-from-dysport-dose-escalation-study/2473018/Top-line results from a Phase 2 dose escalation study show that significantly more subjects treated with Dysport® at all four doses achieved a composite two grade improvement responder rate than those treated with placebo at one month. The study accessed the duration of ef